Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.48 Analyst target: $3.30 Upside: 580.97%
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.